Systemic sclerosis & Raynaud's
Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?
Authors' conclusion
The outcome of patients with both SSc and COVID-19 improved significantly over time because of intrinsic and extrinsic factors.
Study context
- Population
- Patients with both systemic sclerosis (SSc) and COVID-19 registered in EUSTAR, April 2020–April 2021
- Participants
- 333 patients
- Exposure
- COVID-19 waves 2 and 3 vs wave 1
- Outcome
- Severe outcome: death, ICU stay, or ventilatory support
Methodological detailsmulticentre, EUSTAR registry, multivariate logistic regression
- Multicentre
- EUSTAR registry
- Multivariate logistic regression
Main finding
As reported in the abstract
Severe COVID-19 (death, ICU stay or ventilatory support)
P < 0.001
- Severe outcome, overall
- 57 (17%)
Observational data: associations, not effects.
Further findings
Hospitalization — Wave 1 vs Waves 2 and 3
P < 0.001
Ventilatory support — Wave 1 vs Waves 2 and 3
P = 0.001
Death — Wave 1 vs Waves 2 and 3
P = 0.011
- Death — Deaths, overall
- 30 (9%)
Patient characteristics and treatment over waves 1 to 3
- Patients significantly younger, more often men, less frequent arterial hypertension and less SSc cardiac involvement over waves 1 to 3
- Significantly less medium to high doses of corticosteroids
Original publication
Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care Res (Hoboken). Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →